Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

NIHR Health Technology Aassessment is funding a new study looking at the risks and benefits of first line osteoporosis medications (oral bisphosphonates) amongst patients suffering from chronic kidney disease, led by Associate Professor Daniel Prieto-Alhambra of NDORMS.

Around 3 million people suffer from osteoporosis in the UK and about 27% of those have at least moderate chronic kidney disease (CKD).

Osteoporosis weakens bones and makes them fragile and more likely to break. Currently, first line therapies for the prevention of the condition include oral bisphosphonates, a type of drug known to reduce the risk of fracture and improve bone density within 6 months of therapy. However, little is known about the impact of this type of drug on chronic kidney disease.

The new study, to start in December this year, will provide key information on the association between oral bisphosphonates and both the rates of fractures (benefit) and potential side effects amongst patients with different stages of CKD. This will benefit not only patients and but also the NHS: clarifying whether the use of this type of drug is safe and effective in patients with CKD will enable an informed decision on whether UK patients with CKD should be treated with these drugs.

Associate Professor Daniel Prieto-Alhambra says: "Patients with renal impairment have an increased risk of fractures. However, the most commonly used drugs to prevent these could have serious side effects for them. We will use data from thousands of patients with CKD who have been previously exposed to bisphosphonates to determine whether these medications are both safe and effective for them."

The study will use 'real life' data as routinely collected in NHS clinical practice, including primary and hospital care anonymised records for millions of UK people, ensuring the study fully represents the general population of patients. This will make our findings a key piece of information for clinicians treating and patients suffering from kidney impairment considering bisphosphonate therapy across the NHS.

You can read more about this study here.

 

This project is funded by the National Institute for Health Research Health Technology Assessment, with project number 14/36/02: Risks and benefits of bisphosphonate use in patients with chronic kidney disease: a population-based cohort study.

Similar stories

Clinical trial finds Azithromycin has no benefit against COVID-19

Main OCTRU

A clinical trial by University of Oxford researchers has confirmed that the antibiotic azithromycin has no clinical benefit in people with moderate COVID-19.

Study reveals the three most important aspects of care for hip fractures

Hip Main OCTRU Research Trauma

Older patients with hip fractures recover better if they receive treatment under the supervision of both a surgeon and a specialist in elderly care; are checked to avoid future falls; and are assessed for memory problems.

Major ERC funding awarded to Professor Michael Dustin

Awards Kennedy Main

Professor Michael Dustin and an international team of collaborators have been awarded a €10M grant from the European Research Council (ERC) to develop a new biotechnology around supramolecular attack particles (SMAPs) engineered to kill cancer cells.

The role of mAbs (neutralising monoclonal antibodies) in the fight against COVID-19

Main Research

Neutralising mAbs, a form of anti-viral medicine, are being explored as an attractive option to treat symptoms of COVID-19 and in some cases prevent infection. But what are the pros and cons of this type of treatment and what should regulators consider before granting approval?

Professor Michael Dustin elected to the National Academy of Sciences

Awards Kennedy Main

Recognised for his outstanding contributions to the field of immunology, Michael becomes the fourth Kennedy professor to be elected to the Academy.

Small mechanical forces in immune cells measured at unprecedented sensitivity

Kennedy Main Research

Oxford researchers have used advanced microscopy techniques to measure previously unseen forces generated by cells during an immune response; a breakthrough for mechanobiology and future advances in health and disease.